B. Wefer
University of Kiel
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by B. Wefer.
Urologe A | 2007
C. Seif; S. Boy; B. Wefer; R. Dmochowski; P.M. Braun; K.P. Jünemann
This article shall give a state-of-the-art review about the treatment of neurogenic and idiopathic detrusor overactivity with botulinum toxin injections into the detrusor muscle. We searched PubMed for original articles up to December 2006. Abstracts published at international congresses were also considered if they provided substantial new information. Based on this review it appears that a majority of patients with spinal cord injury regains continence after botulinum toxin A injection and that in children with myelomeningocele a significant improvement in continence can also be achieved. A concomitant reduction of intravesical pressure protects the upper urinary tract in these patients. In idiopathic detrusor overactivity, injection of botulinum toxin A also resulted in improvement of continence and reduction of daily micturition frequency. For both indications a high success rate could be achieved with an average duration of the effect of 6 months. Repeated injections into the detrusor seem to have no adverse effects in terms of duration or strength of the effect. Side effects were marginal and systemic side effects were experienced only in individual cases; in some patients with idiopathic detrusor overactivity intermittent self-catheterization was required. Overall intradetrusor injections of botulinum toxin seem to be a new, highly effective, and safe alternative in the treatment of neurogenic and idiopathic detrusor overactivity.
Urologe A | 2008
C. Seif; S. Boy; B. Wefer; R. Dmochowski; P.M. Braun; K.P. Jünemann
This article shall give a state-of-the-art review about the treatment of neurogenic and idiopathic detrusor overactivity with botulinum toxin injections into the detrusor muscle. We searched PubMed for original articles up to December 2006. Abstracts published at international congresses were also considered if they provided substantial new information. Based on this review it appears that a majority of patients with spinal cord injury regains continence after botulinum toxin A injection and that in children with myelomeningocele a significant improvement in continence can also be achieved. A concomitant reduction of intravesical pressure protects the upper urinary tract in these patients. In idiopathic detrusor overactivity, injection of botulinum toxin A also resulted in improvement of continence and reduction of daily micturition frequency. For both indications a high success rate could be achieved with an average duration of the effect of 6 months. Repeated injections into the detrusor seem to have no adverse effects in terms of duration or strength of the effect. Side effects were marginal and systemic side effects were experienced only in individual cases; in some patients with idiopathic detrusor overactivity intermittent self-catheterization was required. Overall intradetrusor injections of botulinum toxin seem to be a new, highly effective, and safe alternative in the treatment of neurogenic and idiopathic detrusor overactivity.
Urologe A | 2008
C. Seif; S. Boy; B. Wefer; R. Dmochowski; P.M. Braun; K.P. Jünemann
This article shall give a state-of-the-art review about the treatment of neurogenic and idiopathic detrusor overactivity with botulinum toxin injections into the detrusor muscle. We searched PubMed for original articles up to December 2006. Abstracts published at international congresses were also considered if they provided substantial new information. Based on this review it appears that a majority of patients with spinal cord injury regains continence after botulinum toxin A injection and that in children with myelomeningocele a significant improvement in continence can also be achieved. A concomitant reduction of intravesical pressure protects the upper urinary tract in these patients. In idiopathic detrusor overactivity, injection of botulinum toxin A also resulted in improvement of continence and reduction of daily micturition frequency. For both indications a high success rate could be achieved with an average duration of the effect of 6 months. Repeated injections into the detrusor seem to have no adverse effects in terms of duration or strength of the effect. Side effects were marginal and systemic side effects were experienced only in individual cases; in some patients with idiopathic detrusor overactivity intermittent self-catheterization was required. Overall intradetrusor injections of botulinum toxin seem to be a new, highly effective, and safe alternative in the treatment of neurogenic and idiopathic detrusor overactivity.
Aktuelle Urologie | 2007
A. Bannowsky; B. Wefer; D. Osmonov; J.A. Sotelino; N. Filippow; C.M. Naumann; Ch. van der Horst; K.P. Jünemann; S. Hautmann
Mesonephroid adenocarcinoma of the bladder may be a malignant form of nephrogenic adenoma or nephroid metaplasia. The lesion is extremely rare in the urinary bladder, and to our knowledge 19 cases have been reported in the literature. We report two cases of mesonephroid adenocarcinoma of the bladder which were treated by radical cystectomy.
Brain | 2006
Jan Herzog; Peter H. Weiss; Ann Assmus; B. Wefer; C. Seif; Peter M. Braun; Hans Herzog; Jens Volkmann; Günther Deuschl; Gereon R. Fink
Brain | 2007
Jan Herzog; Peter Weiss; Ann Assmus; B. Wefer; C. Seif; Peter M. Braun; Marcus O. Pinsker; Hans Herzog; Jens Volkmann; Günther Deuschl; Gereon R. Fink
World Journal of Urology | 2010
B. Wefer; Birgit Ehlken; Jörn Bremer; Harald Burgdörfer; Burkhard Domurath; C. Hampel; Johannes Kutzenberger; C. Seif; Karl D. Sievert; Karin Berger; Jürgen Pannek
European Urology | 2004
André Reitz; A. Haferkamp; Tatiana Kyburz; Peter A. Knapp; B. Wefer; Brigitte Schurch
European Urology | 2004
André Reitz; Sibylle Bretscher; Peter A. Knapp; Michael Müntener; B. Wefer; Brigitte Schurch
World Journal of Urology | 2008
A. Bannowsky; B. Wefer; Peter M. Braun; Klaus-Peter Jünemann